Medscape is available in 5 Language Editions – Choose your Edition here.


Pediatric Social Phobia and Selective Mutism

  • Author: Bettina E Bernstein, DO; Chief Editor: Caroly Pataki, MD  more...
Updated: May 15, 2014


Selective mutism is defined by the Diagnostic and Statistical Manual of Mental Health Disorders, 5th Edition (DSM-5) as “an anxiety disorder, given that a large majority of children with selective mutism are anxious.”[1] Formerly, in the Diagnostic and Statistical Manual of Mental Health Disorders, Edition IV-Text Revision (DSM-IV-TR),[2] selective mutism was classified in the section “Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence.” The diagnostic criteria for selective mutism are largely unchanged from DSM-IV-TR.

Selective mutism is a disorder in which an individual is not able to speak aloud in specific situations when there is an expectation of conversational speech.[2] Communicative language is generally intact in such individuals, although selective mutism can coexist with language and communication disorders.

Selective mutism can be accompanied by other anxiety disorders such as separation anxiety disorder, social anxiety disorder (formerly called social phobia), agoraphobia, and panic disorder, as well as by shyness and anxiety; however, it can also exist without other anxiety-related disorders.[3]

Selective mutism generally occurs by age 5 years; however, usually it is not diagnosed until the child starts school. In some cases, adolescents and adults continue to experience an inability to speak in public. This inability is generally most disabling at school, as the child cannot be assertive and speak when called on by teachers. In adults, functional impairment occurs when public speaking or lecturing is required in one's vocation. Often, the child with selective mutism designates a friend or close family member to serve as an interpreter of communication and whispers into that person's ear, so that communication occurs with the designated person as intermediary.

Often, selective mutism can coexist with social phobia, also known as social anxiety, and is defined by marked and persistent fear of social or performance situations in which embarrassment may occur; exposure to the social or performance situation almost always causes an anxiety reaction such as a situationally bound or situationally predisposed panic attack.

Selective mutism can also be the precursor to agoraphobia and/or panic disorder. Agoraphobia is a specific phobia in which the individual fears being in crowded places. People with agoraphobia often become homebound. Panic disorder can result in significant disability and iatrogenically induced illness, especially in situations when invasive medical testing is done, because the severity of symptoms such as chest pain and palpitations and medical testing can intensify the severity of the panic symptoms.

The anxiety reaction is not due to psychosis; individuals are able to recognize their fears as excessive and unreasonable. However, the ability to fully comprehend that the reaction is out of proportion to the precipitant may be less complete in children and may depend on their cognitive-developmental level of functioning due to deficits in emotional regulation. Recent studies have looked at physiological measures reflecting the severity of anxiety. Children with selective mutism were compared with children with social phobia in a study of 35 children (average age, 8 y). Those with social phobia and selective mutism had chronically higher levels of arousal as reflected by respiratory sinus arrhythmia and skin conductance levels. This may help explain why children with selective mutism may appear to others to not be overtly anxious; their silence may serve to decrease outward signs of anxiety observable by others.[4]

Studies that use physiological measures to objectively measure the severity of anxiety have shown that children with selective mutism and social anxiety as compared with children with social phobia alone have chronically higher levels of arousal (more intense anxiety) as reflected in the presence of respiratory sinus arrhythmia and skin conductance levels. Children with selective mutism may appear to others to not be overtly anxious, especially because of their silence, as their anxiety is not directly observable by others.[4]

Selective mutism significantly impairs the individual's level of functioning, as the individual is unable to complete required educational, social, and family tasks, and the emotional distress engendered in situations requiring the person to speak out loud can result in school refusal.[5]

Selective mutism is a disorder that first occurs in childhood and can continue into adolescence and adulthood. In adults with this disorder, functional impairment occurs when public speaking or lecturing are required in one's vocation. Severe social anxiety may not be evident, as the person may actually function in a relaxed manner when using nonverbal (ie, gestures, signing) communication styles.[6]

Shyness does not necessarily persist in adolescents with social anxiety disorder. A study by Burstein et al found that almost 50% of a group rated themselves shy; however, only 12% of adolescents who identified themselves as shy actually met criteria for lifetime incidence of social anxiety disorder as measured by the World Health Organization Composite International Diagnostic Interview 3.0, and 5.2% of adolescents who did not identify as having shyness had social phobia.[7]

There is significant comorbidity of social phobia with anxiety disorders, major depressive disorder, and drug use disorders, without regard to the presence or absence of shyness. Adolescents with shyness were more likely to report agoraphobia compared with the no-shyness group. Adolescents with social phobia versus adolescents with shyness had greater impairment in the areas of school/work, family relationships, and social life; however, they were no more likely to obtain professional treatment. Eighty percent of adolescents with social phobia failed to seek or to obtain professional treatment for their anxiety, and rates of prescribed medication use were systematically low across groups: 2.3% of adolescents with social phobia and 0.9% of adolescents with shyness used paroxetine.

Adolescent gender did not have a significant effect on the prevalence of social phobia. However, culture can cause parents to underreport anxiety; a clinically referred sample of 408 parent-youth dyads of African American adolescents versus Latino and white adolescents that used the Screen for Child Anxiety Related Emotional Disorders (SCARED) found that parents tended to significantly underreport anxiety symptoms.[8]



Serotonin pathways may be involved in the mediation of the anxious and obsessive qualities of selective mutism. This theory is reinforced by animal models of phobic behavior and by response to commonly prescribed medications such as selective serotonin reuptake inhibitors (SSRIs), such as paroxetine, sertraline, or older heterocyclic-type antidepressants (eg, clomipramine [Anafranil]).[9]

A study of 106 children with selective mutism also included 1028 young adults who completed measures of social interactional anxiety and 920 young adults with childhood behavioral inhibition.[10] The study found a nominal significance (P = .018) for association of selective mutism with rs2710102, which, with rs6944808, was part of a common haplotype associated with selective mutism (permutation P = .022). Adjusting for sex and ancestral proportion, each copy of the rs2710102*, a risk allele in the young adults, was associated with increased odds of being more than 1 standard deviation above the mean on the Social Interactional Anxiety Scale (odds ratio = 1.33; P = .015) and Retrospective Self-Report of Inhibition (odds ratio = 1.40; P = .010).

This study is very encouraging that future genome-wide association studies might reflect an association of early onset variant of social anxiety disorder and selective mutism to a susceptibility gene, contactin-associated protein-like 2 (CNTNAP2), which has been found in other studies in relation to autism spectrum disorders. rs2710102 is a possible nonrisk allele for autism spectrum disorders and specific language impairment.

Behavioral inhibition is an early childhood temperament characterized by fearful responses to novelty and avoidance of social interactions. During adolescence, a subset of children with stable childhood behavioral inhibition develop social anxiety disorder and concurrently exhibit increased error monitoring.

Increased error monitoring in 7-year-olds who were characterized regarding behavioral inhibition at age 24 and 36 months prospectively predicted risk for symptoms of social phobia at age 9 years in this study of 291 children; Those high in behavioral inhibition had increased error monitoring at age 7 years, as indexed by larger (ie, more negative) error-related negativity amplitudes. In addition, early behavioral inhibition was related to later childhood social phobia symptoms at age 9 years among children with a large difference in amplitude between error-related negativity and correct-response negativity at age 7 years.

Heightened error monitoring predicts risk for later social phobia symptoms in children with high behavioral inhibition. Research assessing response monitoring in children with behavioral inhibition may refine our understanding of the mechanisms underlying risk for later anxiety disorders and the possible need for prevention efforts.[11]

Adolescents with early-life behavioral inhibition, similar to adolescents with social phobia, did not have striatal sensitivity to valence or self-reported affective sensitivity to incentive magnitude, which supported specificity in features of generalized anxiety disorder relative to social phobia or behavioral inhibition. Distinct striatal subregion responses showed a more generalized pattern of striatal response in adolescents with social phobia when compared with their healthy peers, and this pattern emerged across the caudate, putamen, and nucleus accumbens. Widespread magnitude-related incentive activations had underlied psychological states common to behavioral inhibition and social phobia, such as performance monitoring or sensitivity to feedback and caudate hyperactivation in social phobia, and behavioral inhibition suggested anomalies in goal-based processes, which were more strongly modulated in the caudate rather than in the putamen or nucleus accumbens.[12]

Two efferent feedback pathways to the auditory periphery may play a role in monitoring self-vocalization: the middle-ear acoustic reflex (MEAR) and the medial olivocochlear bundle (MOCB) reflex. In selective mutism compared with a group of normally developing control children, a significantly higher proportion of selective mutism children had abnormal MEAR and MOCB function (58.6% and 38%, respectively) compared with controls (9.7% and 8%, respectively). The overall prevalence of abnormal MEAR and/or MOCB function was significantly higher in the selective mutism group (71%) compared with controls (16%).[13]




United States

The average age of onset of all anxiety disorders is 11 years, which reflects that anxiety disorders are common in children and adolescents.

In the National Comorbidity Survey-Replication-Adolescent Supplement, an epidemiologic sample of 10,123 adolescents in the United States, prevalence estimates for the different anxiety disorders were as follows: generalized anxiety disorder, 2.2%; social phobia, 9.1%; specific phobia, 19.3%; panic disorder, 2.3%; and separation anxiety, 7.6%.[14]

Social phobia is the third most common mental health disorder after depression.[15] Bergman et al (2002) reported that the prevalence rate of selective mutism was 0.71% but ranged from 0.08% to 1.9% depending on the population studied.[16]

Selective mutism is seen in fewer than 1% of children observed in mental health settings and is reported about 2-2.5 times more often in females than in males. The onset of selective mutism usually occurs during the preschool years, and it is generally not diagnosed until the child attends school and often can be misdiagnosed as oppositional defiant disorder because of the significant features of oppositionality and defiance that frequently accompany the child's refusal to speak especially in the school setting. With increased chronological age, a significant percentage of children "outgrow" the selective mutism however some children continue to have difficulty with public speaking and exhibit sparse language production compared with their age mates.[17]


Generally, mortality does not result directly from selective mutism, except in cases of associated major depression resulting in suicide or reaction to medication treatment (sudden cardiac death with imipramine or clonidine) or adverse reaction such as newly onset suicidality following therapy with SSRIs or other antidepressants. A high morbidity rate is observed, with many missed school or workdays; the child often develops associated school refusal because of the anxiety associated with being asked to speak in class.[17]

There is a potential risk of iatrogenically induced illness in situations in which there is severe physical symptoms of panic disorder due to the likelihood that invasive medical testing might be performed if symptoms include palpitations or chest pain.[18]


Selective mutism is diagnosed more often in females than in males, with a female-to-male ratio of about 2-2.5:1.[16]


Onset of selective mutism may occur as early as school age but generally occurs by mid adolescence following a childhood history of social inhibition or excessive shyness.[3]

The onset of selective mutism is often abrupt, occurring after a stressor or humiliating social experience and typically occurs when a child first attends school (either kindergarten or preschool). Over time, anxiety levels tend to increase as children do not "grow out of" selective mutism.[19] Selective mutism persists as low self-confidence, shyness, and discomfort in social situations, often persisting into adulthood when speaking in public is required.[20]

Contributor Information and Disclosures

Bettina E Bernstein, DO Distinguished Fellow, American Academy of Child and Adolescent Psychiatry; Distinguished Fellow, American Psychiatric Association; Clinical Assistant Professor of Neurosciences and Psychiatry, Philadelphia College of Osteopathic Medicine; Clinical Affiliate Medical Staff, Department of Child and Adolescent Psychiatry, Children's Hospital of Philadelphia; Consultant to theVillage, Private Practice; Consultant PMHCC/CBH at Family Court, Philadelphia

Bettina E Bernstein, DO is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry, American Psychiatric Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Caroly Pataki, MD Health Sciences Clinical Professor of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, David Geffen School of Medicine

Caroly Pataki, MD is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry, New York Academy of Sciences, Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Chief Editor

Caroly Pataki, MD Health Sciences Clinical Professor of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, David Geffen School of Medicine

Caroly Pataki, MD is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry, New York Academy of Sciences, Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Additional Contributors

Chet Johnson, MD Professor of Pediatrics, Associate Director and Developmental-Behavioral Pediatrician, KU Center for Child Health and Development, Shiefelbusch Institute for Life Span Studies; Assistant Dean, Faculty Affairs and Development, University of Kansas School of Medicine

Chet Johnson, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.

  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. 4th ed. Washington, DC: American Psychiatric Publishing; 2000.

  3. Manassis K. Silent suffering: understanding and treating children with selective mutism. Expert Rev Neurother. 2009 Feb. 9(2):235-43. [Medline].

  4. Scott S, Beidel DC. Selective mutism: an update and suggestions for future research. Curr Psychiatry Rep. 2011 Aug. 13(4):251-7. [Medline].

  5. Kearney CA, Albano AM. The functional profiles of school refusal behavior. Diagnostic aspects. Behav Modif. 2004 Jan. 28(1):147-61. [Medline].

  6. Sharkey L, Mc Nicholas F. Female monozygotic twins with selective mutism--a case report. J Dev Behav Pediatr. 2006 Apr. 27(2):129-33. [Medline].

  7. Burstein M, Ameli-Grillon L, Merikangas KR. Shyness versus social phobia in US youth. Pediatrics. 2011 Nov. 128(5):917-25. [Medline].

  8. Dirks MA, Weersing VR, Warnick E, Gonzalez A, Alton M, Dauser C. Parent and youth report of youth anxiety: evidence for measurement invariance. J Child Psychol Psychiatry. 2014 Mar. 55(3):284-91. [Medline].

  9. Yeganeh R, Beidel DC, Turner SM. Selective mutism: more than social anxiety?. Depress Anxiety. 2006. 23(3):117-23. [Medline].

  10. Stein MB, Yang BZ, Chavira DA, et al. A common genetic variant in the neurexin superfamily member CNTNAP2 is associated with increased risk for selective mutism and social anxiety-related traits. Biol Psychiatry. 2011 May 1. 69(9):825-31. [Medline].

  11. Lahat A, Lamm C, Chronis-Tuscano A, Pine DS, Henderson HA, Fox NA. Early behavioral inhibition and increased error monitoring predict later social phobia symptoms in childhood. J Am Acad Child Adolesc Psychiatry. 2014 Apr. 53(4):447-55. [Medline].

  12. Guyer AE, Choate VR, Detloff A, Benson B, Nelson EE, Perez-Edgar K. Striatal functional alteration during incentive anticipation in pediatric anxiety disorders. Am J Psychiatry. 2012 Feb. 169(2):205-12. [Medline].

  13. Muchnik C, Ari-Even Roth D, Hildesheimer M, Arie M, Bar-Haim Y, Henkin Y. Abnormalities in auditory efferent activities in children with selective mutism. Audiol Neurootol. 2013. 18(6):353-61. [Medline].

  14. Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication--Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010 Oct. 49(10):980-9. [Medline]. [Full Text].

  15. Kopp S, Gillberg C. Selective mutism: a population-based study: a research note. J Child Psychol Psychiatry. 1997 Feb. 38(2):257-62. [Medline].

  16. Bergman RL, Piacentini J, McCracken JT. Prevalence and description of selective mutism in a school-based sample. J Am Acad Child Adolesc Psychiatry. 2002 Aug. 41(8):938-46. [Medline].

  17. Cunningham CE, McHolm AE, Boyle MH. Social phobia, anxiety, oppositional behavior, social skills, and self-concept in children with specific selective mutism, generalized selective mutism, and community controls. Eur Child Adolesc Psychiatry. 2006 Aug. 15(5):245-55. [Medline].

  18. Siegel RS, Dickstein DP. Anxiety in adolescents: Update on its diagnosis and treatment for primary care providers. Adolesc Health Med Ther. 2012. 3:1-16. [Medline].

  19. Steinhausen HC, Wachter M, Laimböck K, Metzke CW. A long-term outcome study of selective mutism in childhood. J Child Psychol Psychiatry. 2006 Jul. 47(7):751-6. [Medline].

  20. Remschmidt H, Poller M, Herpertz-Dahlmann B, Hennighausen K, Gutenbrunner C. A follow-up study of 45 patients with elective mutism. Eur Arch Psychiatry Clin Neurosci. 2001 Dec. 251(6):284-96. [Medline].

  21. Dammann O, Naples M, Bednarek F, Shah B, Kuban KC, O''Shea TM, et al. SNAP-II and SNAPPE-II and the Risk of Structural and Functional Brain Disorders in Extremely Low Gestational Age Newborns: The ELGAN Study. Neonatology. 2009 Aug 11. 97(2):71-82. [Medline]. [Full Text].

  22. Politi K, Kivity S, Goldberg-Stern H, Halevi A, Shuper A. Selective mutism and abnormal electroencephalography (EEG) tracings. J Child Neurol. 2011 Nov. 26(11):1377-82. [Medline].

  23. Viana AG, Beidel DC, Rabian B. Selective mutism: a review and integration of the last 15 years. Clin Psychol Rev. 2009 Feb. 29(1):57-67. [Medline].

  24. Scharfstein L, Alfano C, Beidel D, Wong N. Children with generalized anxiety disorder do not have peer problems, just fewer friends. Child Psychiatry Hum Dev. 2011 Dec. 42(6):712-23. [Medline]. [Full Text].

  25. Williford A, Boulton A, Noland B, Little TD, Kärnä A, Salmivalli C. Effects of the KiVa anti-bullying program on adolescents' depression, anxiety, and perception of peers. J Abnorm Child Psychol. 2012 Feb. 40(2):289-300. [Medline].

  26. Wong P. Selective mutism: a review of etiology, comorbidities, and treatment. Psychiatry (Edgmont). 2010 Mar. 7(3):23-31. [Medline]. [Full Text].

  27. Carbone D, Schmidt LA, Cunningham CC, McHolm AE, Edison S, St Pierre J, et al. Behavioral and socio-emotional functioning in children with selective mutism: a comparison with anxious and typically developing children across multiple informants. J Abnorm Child Psychol. 2010 Nov. 38(8):1057-67. [Medline].

  28. Guntheroth W. Link among mitral valve prolapse, anxiety disorders, and inheritance. Am J Cardiol. 2007 May 1. 99(9):1350. [Medline].

  29. Maeda F, Nathan JH. Understanding taijin kyofusho through its treatment, Morita therapy. J Psychosom Res. 1999 Jun. 46(6):525-30. [Medline].

  30. Needleman H. Lead poisoning. Annu Rev Med. 2004. 55:209-22. [Medline].

  31. Castillo EM, Butler IJ, Baumgartner JE, Passaro A, Papanicolaou AC. When epilepsy interferes with word comprehension: findings in Landau-Kleffner syndrome. J Child Neurol. 2008 Jan. 23(1):97-101. [Medline].

  32. Kennard BD, Silva SG, Mayes TL, Rohde P, Hughes JL, Vitiello B, et al. Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. Am J Psychiatry. 2009 Mar. 166(3):337-44. [Medline].

  33. Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry. 2009 Apr. 166(4):418-26. [Medline].

  34. Goldberg EM, Titulaer M, de Blank PM, Sievert A, Ryan N. Anti-N-methyl-D-aspartate receptor-mediated encephalitis in infants and toddlers: case report and review of the literature. Pediatr Neurol. 2014 Feb. 50(2):181-4. [Medline].

  35. Schum RL. Language screening in the pediatric office setting. Pediatr Clin North Am. 2007 Jun. 54(3):425-36, v. [Medline].

  36. Letamendi AM, Chavira DA, Hitchcock CA, Roesch SC, Shipon-Blum E, Stein MB. Selective Mutism Questionnaire: Measurement Structure and Validity. J Am Acad Child Adolesc Psychiatry. 2008 Aug 8. [Medline].

  37. March JS, Parker JD, Sullivan K, et al. The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry. 1997 Apr. 36(4):554-65. [Medline].

  38. Kaufman J, Birmaher B, Brent DA, et al. K-SADS-PL. J Am Acad Child Adolesc Psychiatry. 2000 Oct. 39(10):1208. [Medline].

  39. Birmaher B, Khetarpal S, Brent D, et al. The Screen for Child Anxiety Related Emotional Disorders (SCARED): scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry. 1997 Apr. 36(4):545-53. [Medline].

  40. Scaini S, Battaglia M, Beidel DC, Ogliari A. A meta-analysis of the cross-cultural psychometric properties of the Social Phobia and Anxiety Inventory for Children (SPAI-C). J Anxiety Disord. 2012 Jan. 26(1):182-8. [Medline].

  41. Ponzurick JM. Selective mutism: a team approach to assessment and treatment in the school setting. J Sch Nurs. 2012 Feb. 28(1):31-7. [Medline].

  42. Lang R, Regester A, Mulloy A, Rispoli M, Botout A. Behavioral intervention to treat selective mutism across multiple social situations and community settings. J Appl Behav Anal. 2011 Fall. 44(3):623-8. [Medline]. [Full Text].

  43. Kearney CA. School absenteeism and school refusal behavior in youth: a contemporary review. Clin Psychol Rev. 2008 Mar. 28(3):451-71. [Medline].

  44. O'Reilly M, McNally D, Sigafoos J, Lancioni GE, Green V, Edrisinha C, et al. Examination of a social problem-solving intervention to treat selective mutism. Behav Modif. 2008 Mar. 32(2):182-95. [Medline].

  45. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007 Apr 18. 297(15):1683-96. [Medline].

  46. Cooper WO, Callahan ST, Shintani A, Fuchs DC, Shelton RC, Dudley JA. Antidepressants and suicide attempts in children. Pediatrics. 2014 Feb. 133(2):204-10. [Medline].

  47. Sharkey L, Mc Nicholas F, Barry E, Begley M, Ahern S. Group therapy for selective mutism - a parents' and children's treatment group. J Behav Ther Exp Psychiatry. 2008 Dec. 39(4):538-45. [Medline].

  48. Khalsa MK, Greiner-Ferris JM, Hofmann SG, Khalsa SB. Yoga-Enhanced Cognitive Behavioural Therapy (Y-CBT) for Anxiety Management: A Pilot Study. Clin Psychol Psychother. 2014 May 7. [Medline].

  49. Manassis K, Tannock R. Comparing interventions for selective mutism: a pilot study. Can J Psychiatry. 2008 Oct. 53(10):700-3. [Medline].

  50. Anyfantakis D, Botzakis E, Mplevrakis E, Symvoulakis EK, Arbiros I. Selective mutism due to a dog bite trauma in a 4-year-old girl: a case report. J Med Case Rep. 2009 Nov 3. 3:100. [Medline]. [Full Text].

  51. Evans CE, Sebastian J. Serotonin syndrome. Emerg Med J. 2007 Apr. 24(4):e20. [Medline]. [Full Text].

  52. Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH Jr, Watson WJ. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc. 2009. 84(1):23-7. [Medline]. [Full Text].

  53. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006 Feb 9. 354(6):579-87. [Medline].

  54. Bond GR, Garro AC, Gilbert DL. Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clin Toxicol (Phila). 2007. 45(2):182-5. [Medline].

  55. Chavira DA, Shipon-Blum E, Hitchcock C, Cohan S, Stein MB. Selective mutism and social anxiety disorder: all in the family?. J Am Acad Child Adolesc Psychiatry. 2007 Nov. 46(11):1464-72. [Medline].

  56. Cheung AH, Emslie GJ, Mayes TL. The use of antidepressants to treat depression in children and adolescents. CMAJ. 2006 Jan 17. 174(2):193-200. [Medline].

  57. Cohan SL, Chavira DA, Shipon-Blum E, Hitchcock C, Roesch SC, Stein MB. Refining the classification of children with selective mutism: a latent profile analysis. J Clin Child Adolesc Psychol. 2008 Oct. 37(4):770-84. [Medline].

  58. Hayward C, Killen JD, Kraemer HC, Taylor CB. Linking self-reported childhood behavioral inhibition to adolescent social phobia. J Am Acad Child Adolesc Psychiatry. 1998 Dec. 37(12):1308-16. [Medline].

  59. Hudson JL, Comer JS, Kendall PC. Parental responses to positive and negative emotions in anxious and nonanxious children. J Clin Child Adolesc Psychol. 2008 Apr. 37(2):303-13. [Medline].

  60. Huska MT, Catalano G, Catalano MC. Serotonin syndrome associated with the use of escitalopram. CNS Spectr. 2007 Apr. 12(4):270-4. [Medline].

  61. Kearney CA, Vecchio JL. When a child won't speak. J Fam Pract. 2007 Nov. 56(11):917-21. [Medline].

  62. Kennard B, Silva S, Tonev S, Rohde P, Hughes J, Vitiello B, et al. Remission and Recovery in the Treatment for Adolescents With Depression Study (TADS): Acute and Long-Term Outcomes. J Am Acad Child Adolesc Psychiatry. 2009 Jan 2. [Medline].

  63. Klein DF. The Flawed Basis for FDA Post-Marketing Safety Decisions: The Example of Anti-Depressantsand Children. Neuropsychopharmacology. 2005 Dec 14. [Medline].

  64. Looper KJ. Potential medical and surgical complications of serotonergic antidepressant medications. Psychosomatics. 2007 Jan-Feb. 48(1):1-9. [Medline].

  65. McInnes A, Manassis K. When silence is not golden: an integrated approach to selective mutism. Semin Speech Lang. 2005 Aug. 26(3):201-10. [Medline].

  66. [Guideline] Nelson LS, Erdman AR, Booze LL, et al. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007. 45(4):315-32. [Medline].

  67. Packer S, Berman SA. Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid. Am J Psychiatry. 2007 Feb. 164(2):346-7. [Medline].

  68. Reinblatt SP, Riddle MA. The pharmacological management of childhood anxiety disorders: a review. Psychopharmacology (Berl). 2007 Mar. 191(1):67-86. [Medline].

  69. Reinblatt SP, Walkup JT. Psychopharmacologic treatment of pediatric anxiety disorders. Child Adolesc Psychiatr Clin N Am. 2005 Oct. 14(4):877-908, x. [Medline].

  70. Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache. 2007 Feb. 47(2):266-9. [Medline].

  71. Sharkey L, McNicholas F. More than 100 years of silence', elective mutism: a review of the literature. Eur Child Adolesc Psychiatry. 2008 Aug. 17(5):255-63. [Medline].

  72. Sharp WG, Sherman C, Gross AM. Selective mutism and anxiety: a review of the current conceptualization of the disorder. J Anxiety Disord. 2007. 21(4):568-79. [Medline].

  73. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. Jan 2006. 163:41-47. [Medline].

  74. Smith EG. Association between antidepressant half-life and the risk of suicidal ideation or behavior among children and adolescents: confirmatory analysis and research implications. J Affect Disord. 2009 Apr. 114(1-3):143-8. [Medline].

  75. Varley CK. Treating depression in children and adolescents: what options now?. CNS Drugs. 2006. 20(1):1-13. [Medline].

  76. Vitiello B. Truly independent research? Treatment for Adolescents with Depression Study (TADS). BMJ. 2008 Oct 13. 337:a2070. [Medline].

  77. Wagner KD. Pharmacotherapy for major depression in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun. 29(5):819-26. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.